Trials / Completed
CompletedNCT03284970
Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes
Effect of Interferon Beta-1a SC 44 µg Three Times Weekly (Tiw) (Rebif) and Dimethyl Fumarate (DMF, Tecfidera) on Infections and Lymphocytes in Patients 50 Years or Older From a Single Center Chart Review
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 34 (actual)
- Sponsor
- EMD Serono Research & Development Institute, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This study will be a single center, retrospective, pilot study to determine the effect of Rebif (interferon beta-1a) and Tecfidera (dimethyl fumarate) on infections on total lymphocyte counts, grade of lymphopenia, Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) counts and ratios in subjects aged 50 years and above with Relapsing-Remitting Multiple Sclerosis (RRMS).
Conditions
Timeline
- Start date
- 2017-08-23
- Primary completion
- 2018-05-11
- Completion
- 2018-05-11
- First posted
- 2017-09-15
- Last updated
- 2018-08-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03284970. Inclusion in this directory is not an endorsement.